MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414297 | Name: Bleomycin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bleomycin Free Base is a complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.

Chemical Structure

Bleomycin Free Base
Bleomycin Free Base
CAS#11056-06-7 (free base)

Theoretical Analysis

MedKoo Cat#: 414297

Name: Bleomycin Free Base

CAS#: 11056-06-7 (free base)

Chemical Formula: C55H84N17O21S3+

Exact Mass: 1414.5184

Molecular Weight: 1415.55

Elemental Analysis: C, 46.67; H, 5.98; N, 16.82; O, 23.73; S, 6.79

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
9041-93-4 (sulfate) 11056-06-7 (free base)
Synonym
Bleomycin Free Base; HSDB3208; HSDB-3208; HSDB 3208; CCRIS2754; CCRIS-2754; CCRIS 2754
IUPAC/Chemical Name
(3-(2'-((3S,6R,7S,8S,11S)-1-(6-amino-2-((S)-3-amino-1-(((S)-2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidin-4-yl)-3-((1R)-((3-((4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)(1H-imidazol-4-yl)methyl)-7-hydroxy-11-((R)-1-hydroxyethyl)-6,8-dimethyl-1,4,9,12-tetraoxo-2,5,10,13-tetraazapentadecan-15-yl)-[2,4'-bithiazole]-4-carboxamido)propyl)dimethylsulfonium
InChi Key
OYVAGSVQBOHSSS-WXFSZRTFSA-O
InChi Code
InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
SMILES Code
C[C@H]([C@@H](C(NCCc1scc(c2scc(C(NCCC[S+](C)C)=O)n2)n1)=O)NC([C@H]([C@@H]([C@H](NC([C@H]([C@H](c3nc[nH]c3)OC4OC(C(C(C4OC5OC(C(C(C5O)OC(N)=O)O)CO)O)O)CO)NC(c6c(C)c(N)nc([C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)n6)=O)=O)C)O)C)=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,415.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65(2):81-94. doi: 10.1007/BF02034932. PMID: 1711838. 2: Lazo JS, Sebti SM. Bleomycin. Cancer Chemother Biol Response Modif. 1997;17:40-5. PMID: 9551207. 3: Lazo JS. Bleomycin. Cancer Chemother Biol Response Modif. 1999;18:39-45. PMID: 10800476. 4: Lazo JS, Sebti SM. Bleomycin. Cancer Chemother Biol Response Modif. 1994;15:44-50. PMID: 7540032. 5: Kong J, Yi L, Xiong Y, Huang Y, Yang D, Yan X, Shen B, Duan Y, Zhu X. The discovery and development of microbial bleomycin analogues. Appl Microbiol Biotechnol. 2018 Aug;102(16):6791-6798. doi: 10.1007/s00253-018-9129-8. Epub 2018 Jun 6. PMID: 29876605. 6: Lester EP, Matz GJ. Bleomycin. Otolaryngol Head Neck Surg (1979). 1979 Jul- Aug;87(4):399-400. doi: 10.1177/019459987908700401. PMID: 92001. 7: Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008 Oct;34(10):1299-313. doi: 10.1111/j.1524-4725.2008.34281.x. Epub 2008 Jun 27. PMID: 18616538. 8: Chen H, Cui J, Wang P, Wang X, Wen J. Enhancement of bleomycin production in Streptomyces verticillus through global metabolic regulation of N-acetylglucosamine and assisted metabolic profiling analysis. Microb Cell Fact. 2020 Feb 13;19(1):32. doi: 10.1186/s12934-020-01301-8. PMID: 32054531; PMCID: PMC7017467. 9: Povirk LF, Austin MJ. Genotoxicity of bleomycin. Mutat Res. 1991 Mar;257(2):127-43. doi: 10.1016/0165-1110(91)90022-n. PMID: 1706477. 10: Douglas KT, Ratwatte HA, Thakrar N. Photoreactivity of bleomycin and its implications. Bull Cancer. 1983;70(5):372-80. PMID: 6199058.

View History

Adomeglivant, (+)-

Adomeglivant, (+)-